On Wednesday, Shares of AbbVie Inc (NYSE:ABBV), lost -2.11% to $59.29.
AbbVie, declared the launch of the voting contest phase of its annual AbbVie CF Scholarship program. The public is encouraged to visit www.AbbVieCFScholarship.com recently through September 22, 2015 to assist determine who will earn a total of $23,000 to pursue their educational dreams during the 2015-2016 school year.
Earlier this year, 40 extraordinary students living with cystic fibrosis (CF) received $2,500 based on academic excellence, community involvement, creativity and the ability to serve as a positive role model for the CF community. Each of these students now have the opportunity to vie for public votes to earn the title of 2015 Thriving Undergraduate or Graduate Scholar.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Shares of Mylan NV (NASDAQ:MYL), declined -2.38% to $47.56, during its last trading session.
Mylan N.V., declared its intention to commence on Sept. 14, 2015 its formal offer to exchange all outstanding ordinary shares of Perrigo Company plc (NYSE: PRGO). Under the terms of the offer, Perrigo shareholders will receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share.
Mylan Executive Chairman Robert J. Coury also sent a letter to Perrigo Chairman and Chief Executive Officer Joseph Papa reiterating Mylan’s commitment to the transaction and respect for Perrigo and its employees, re-affirming the compelling value of the Mylan offer to Perrigo shareholders, and outlining to Perrigo shareholders their clear and direct pathway to completion of the transaction.
This letter follows Mylan’s Extraordinary General Meeting on Aug. 28, at which Mylan shareholders voted overwhelmingly in favor of the transaction.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
Finally, News Corp (NASDAQ:NWSA), ended its last trade with -0.97% loss, and closed at $13.22.
Move, Inc., a partner of News Corp and operator of realtor.com, declared the recent appointment of Anthony Perry as vice president of Media Sales.
In his role, Perry is responsible for building and executing Move’s advertising business across digital, mobile, and emerging technologies, expanding the reach of the company’s brands and engaging with its audiences.
“We are thrilled that Anthony has joined our sales leadership team,” said Ray Picard, executive vice president of sales for Move. “As we continue to look for opportunities to turbo-charge realtor.com, Anthony’s experience in the traditional media space as well mobile, social and emerging technologies will allow us to deliver increasing value to our media partners.”
News Corporation, a media and information services company, focuses on creating and distributing content to consumers and businesses worldwide. The company distributes content and data products, such as The Wall Street Journal, Factiva, Dow Jones Risk & Compliance, Dow Jones Newswires, Barron’s, MarketWatch, Dow Jones Private Markets, and DJX through various media channels, counting newspapers, newswires, Websites, newsletters, magazines, proprietary databases, conferences, and video, in addition to applications for mobile devices, tablets, and electronic readers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
